Bevacizumab is a monoclonal antibody targeting VEGF and has been shown to play a pro-apoptotic and anti-angiogenic effect on CLL cells in vitro.[12, 13] As a monotherapy, no significant clinical activity was observed with bevacizumab in patients with relapsed refractory CLL.[14] Multiple studies in solid tumors, however, suggest that bevacizumab has its greatest effect in combination with chemotherapy. The gene discussed is VEGFA; the disease is B-cell chronic lymphocytic leukemia.